Whilst laparoscopy surgery is the only definitive diagnostic tool for Endometriosis, our advanced testing technology provides a more cost-effective and accessible screening alternative to assist clinicians in their assessment and management of the disease.
Enabling at-home sample collection, Arelis eliminates the need for regents or expensive capital purchases, making the test highly accessible to those who experience geographical isolation.
Advancing our knowledge of disease using biospectroscopy
Arelis harnesses the power of Artificial intelligence, advanced machine learning and Biospectroscopy - an emerging field in medical diagnostics. It involves analysing the distinct spectral signatures of biological samples like urine or blood to identify molecular compositions. By measuring interactions between light and biomolecules, biospectroscopy offers valuable insights into health conditions, aiding in accurate diagnosis and treatment planning.
Unlike traditional approaches that focus on individual or combinations of biomarkers, our test examines the comprehensive makeup of the sample, encompassing proteins, biomarkers, and potentially undiscovered elements offering the possibility of improved sensitivity and specificity.
Our advanced technology identifies a risk reading for Endometriosis with a Sensitivity and Specificity of >95%.​
We are shifting the biomarker paradigm
and pioneering the evolution of whole sample testing.
If you would like to learn more about our advanced testing, please provide your details here to receive a comprehensive data pack featuring in-depth scientific literature and AI-driven research insights.
